HEALTHSEATTLE TIMES
Loophole in patent law brings ‘miracle drug’ to patients who can’t afford it
A generic version of a breakthrough cystic fibrosis drug, manufactured in Bangladesh, may provide an affordable lifeline for patients who cannot afford the original medication. The drug's availability highlights a loophole in patent law that allows generic production in certain regions.
Related Signal
Adjacent reporting
- Canada and India now have generic Wegovy. Here’s why the U.S. doesn’t.
- STAT+: Supreme Court backs generic drugmaker in ‘skinny labeling’ case
- India’s Generic Copies Dent Eli Lilly’s Sales
- Justices reject holding generic pharmaceutical manufacturers liable for decisions of pharmacists about prescribing their products
- Novo Nordisk lets Canadian patent expire
- India's Biocon on Generic GLP-1 Push